Amarin (AMRN) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

AMRN Amarin

Watchlist

0.612
+0.007+1.16%

Close Feb 14 16:00 ET

0.612
0.0000.00%

Post 20:01 ET

251.90MMarket Cap-6.12P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Tariffs Expected to Bring Pharmaceutical Price Bumps, Shortages -- Market Talk
WSJFeb 10 10:43 ET
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading
MT NewswiresDec 16, 2024 11:10 ET
Amarin Corporation Announces National Reimbursement Approval for VAZKEPA in Italy to Reduce Cardiovascular Risk in High-Risk Patients
Quiver QuantitativeDec 16, 2024 07:12 ET
Executive Reshuffles: JPM, QCOM, DVN and LTC
Seeking AlphaDec 14, 2024 15:54 ET
Press Release: Amarin Appoints Peter Fishman Chief Financial Officer
Dow JonesDec 13, 2024 09:00 ET
Express News | Amarin Appoints Peter Fishman Chief Financial Officer
ReutersDec 13, 2024 09:00 ET

Comments

Tonyco

Dec 16, 2024 16:03

$Amarin (AMRN.US)$
undervalued, oversold
C&E: 156M ST Debt: 9.5M, LT Debt: 8.88M CR: 3.2 QR: 2.08 FCF: -18M
The risk of dilution is low for now. However, cash burn is problematic. Expanded to Euro markets w/2039 patent expiry

Jaguar8

Dec 16, 2024 06:03

NEWS

$Amarin (AMRN.US)$
Amarin Receives National Reimbursement for VAZKEPA® in Italy
Monday, 16th December at 7:00 am
-- Italian Health Authorities Approve VAZKEPA® (icosapent ethyl) for National Reimbursement to Reduce Cardiovascular Risk in Eligible High-Risk Patients1 --
-- Italy is the Third EU5 Market to Grant National Reimbursement; Ninth National Reimbursement for VAZKEPA® Overall in Europe --
-- European Progress Has Advanced Patient Access: Countries That Have Provided Access to VAZKEP...

Jaguar8

Nov 22, 2024 15:53

NEWS

$Amarin (AMRN.US)$
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On November 22, 2024, Amarin Corporation plc (the “Company”) received a notice (the “Extension Notice”) from the Nasdaq Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that Nasdaq has granted the Company an additional 180 calendar days, or until May 19, 2025, to regain compliance with the minimum bid price requi...